TBPH (Theravance Biopharma Inc) Net Profit

Corporate emblem and logo of theravance.com (TBPH)

Price action confirms the financial standing of Theravance Biopharma (TBPH), which focuses on respiratory therapy by leveraging steady demand and partnership agreements for inhalers. The company is developing strategic alliances with industry behemoths to distribute its products. However, reliance on Trelegy payments and uncertainty regarding future developments create risks, with the indicator standing at 0.05.

TBPH (Theravance Biopharma, Inc.) Company Net Income history from 07/04/2022 to 10/10/2026

Financial and market metric breakdowns for Theravance Biopharma, Inc. (TBPH)

- price and consensus price forecast:
Stock Quotes Theravance Corp|TBPH - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Theravance Corp|TBPH - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Theravance Biopharma|TBPH - Company Book Value|Market-to-Book Ratio theravance.com|TBPH - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital Theravance Biopharma|TBPH - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Theravance Biopharma Inc|TBPH - Company Aggregate Debts|Debts to Book Value Theravance Corp|TBPH - Company Long-Term Debt|Company Short-Term Loans and Borrowings Theravance Biopharma|Intermediate Liquidity Ratio theravance.com
- net income and valuation multiples indicators:
TBPH - Net Profit
Fundamental valuation:TBPH Theravance Corp
Flagship merchandise of Theravance Biopharma Inc

Theravance Biopharma strategic alliances for drug commercialization are directly reflected in the company's current net result. This indicator captures real cash flow, separating actual business efficiency from market volatility. The calculation is based on the final cash balance after deducting all operating and financial obligations. A downward curve signals rising costs or declining partnership yields. It is critical for investors to avoid buying at the peak to prevent overpaying.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Aquestive Therapeutics, Inc. - Net Income|Profit After Payment of Taxes SCPH (scPharmaceuticals, Inc.)|Tectonic - Net Profit|Final Profit TNXP (Tonix Pharmaceuticals Holding)|SXTC: Net Profit|Company Net Income Eupraxia Pharmaceuticals Inc. (EPRX)|Company Net Income BioHarvest Sciences Inc.|EXOZ: Final Profit|Net Profit ORMP|Net Profit enterabio.com (ENTX)|MindWalk Holdings - Net Income|abvcpharma.com - Company Net Income|Cumberland Pharmaceuticals Inc. - Net Profit|QNTM - Net Profit|FibroGen Corp (FGEN) - Company Net Income|Company Profit TELO|RANI (Rani Therapeutics Holdings) - Net Profit|Net Income Synergy CHC Corporation (SNYR)|Net Profit RLYB|LEXX - Company Net Income|Pulmatrix Corp - Net Income|Final Profit PTHL|Aptorum - Net Profit|LYRA: Company Net Income|IBO: Net Profit|TNFA - Net Financial Result|Company Net Income cbdMD Inc.|Company Net Income PainReform Corp PRFX|Company Net Income Altamira Therapeutics (CYTO)|LIPO: Profit After Tax|Net Profit OPTN (OptiNose)|Final Profit PIRS|Procaps Group SA - Net Profit|PTPI - Net Profit|Qilian International (QLI) - Company Net Income|acelyrin.com - Final Profit|Company Net Income TFF Pharmaceuticals, Inc.